Hikma Pharmaceuticals (LSE:HIK) delivered revenue and profit growth in 2025 while unveiling a new $250 million share buyback programme and a broad leadership overhaul aimed at strengthening operational execution and long-term strategy.
Core revenue for the year increased 6% to $3.35 billion, while core operating profit rose 3% to $741 million, supported by double-digit expansion in the Branded division and solid contributions from Injectables and the Hikma Rx generics business across North America, the Middle East and North Africa (MENA), and Europe.
Reported operating profit declined year-on-year, reflecting the impact of legal settlements and margin pressures within the Injectables segment. Despite this, the company maintained a strong balance sheet position and increased its dividend by 5%, while continuing to expand its product portfolio with 84 launches during the year, including its first biosimilar product in the United States.
Looking ahead, Hikma announced plans to repurchase up to $250 million of shares in 2026 and provided guidance for modest revenue and profit growth. The company also withdrew its previous medium-term targets following a strategic review of the Injectables business, signalling a reassessment of priorities within the division.
A significant leadership restructuring was also confirmed. Executive Chairman Said Darwazah will transition to focus exclusively on the chief executive role, while a new chair will be appointed. The company will introduce regional deputy CEO positions and has named an acting chief financial officer, moves designed to enhance accountability and organisational agility as Hikma seeks to capitalise on opportunities in biosimilars and specialty injectables.
Hikma Pharmaceuticals’ outlook is supported by strong financial performance and an attractive valuation profile. While technical indicators currently point to a weaker trend, management’s strategic initiatives and positive corporate developments are viewed as supportive of future growth potential.
More about Hikma Pharmaceuticals
Hikma Pharmaceuticals is a UK-headquartered multinational pharmaceutical company specialising in generic and branded medicines. The group operates across North America, the Middle East and North Africa, and Europe, with core activities spanning injectables, branded drugs and the Hikma Rx generics segment. Hikma also invests in innovative healthcare technologies through its venture capital arm, positioning itself as both a manufacturing partner and strategic investor in emerging therapies.
Leave a Reply